![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Femasys Founder Discusses Femaseed Technology Designed to Support Infertility
admin July 5, 2024 ArticleIn an interview with Pharm Exec Associate Editor Don Tracy, Kathy Lee-Sepsick, Founder, CEO, Femasys, offers a description of how Femaseed works to support women who struggle with infertility.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Pharma Pulse 7/4/24: Colder Temperatures May Worsen Asthma Symptoms, New FDA Approved ALZ Drug to Accelerate New Era of Treatment & more
admin July 5, 2024 ArticleThe latest news for pharma industry insiders.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Michael J. Fox Foundation and Parkinson’s UK Award $5.2 Million to Mission Therapeutics for Research into Potential Parkinson’s Treatment
admin July 4, 2024 ArticleMTX325 is in Phase I trials and is believed to be able to modify the course of the disease.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Health In Tech Announces New Partnerships to Expand Health Insurance Options for Employers in Southern Ohio
admin July 4, 2024 ArticleThe company announced that it has partnered with Adena Health and The Ohio State University Health Plan Solutions.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Moderna Awarded $176 Million from the Biomedical Advanced Research and Development Authority to Expedite Development of mRNA-Based Influenza Vaccines
admin July 3, 2024 ArticleFunding from the Biomedical Advanced Research and Development Authority (BARDA) is expected to support the late-stage development and licensure of a pre-pandemic vaccine targeting the H5 influenza virus.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease
admin July 3, 2024 ArticleKisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
As previously announced, Michael assumed the role on July 1.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
FDA Approves New Drug Application for Shorla Oncology’s Tepylute, a Ready-to-Dilute Formulation for the Treatment of Breast and Ovarian Cancer
admin July 2, 2024 ArticleReportedly, the liquid formulation of Tepylute eliminates the need for complex and time-consuming reconstitution, providing consistent dosing accuracy and allowing for timely preparation.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Magnolia Medical Announces New Platform to Reduce Misdiagnosis of Sepsis
admin July 1, 2024 ArticleThe platform utilizes standards set forth in a recently published document from the CDC.
![](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
UltraSight Announces Partnership with Butterfly Garden AI-Marketplace
admin July 1, 2024 ArticleUltraSight will join the AI marketplace.